Incyte Corporation

NasdaqGS:INCY Stock Report

Market Cap: US$14.6b

Incyte Future Growth

Future criteria checks 5/6

Incyte is forecast to grow earnings and revenue by 46.3% and 8.9% per annum respectively. EPS is expected to grow by 45.9% per annum. Return on equity is forecast to be 24.7% in 3 years.

Key information

46.3%

Earnings growth rate

45.9%

EPS growth rate

Biotechs earnings growth26.7%
Revenue growth rate8.9%
Future return on equity24.7%
Analyst coverage

Good

Last updated14 Nov 2024

Recent future growth updates

Recent updates

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Oct 31

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Jun 06
It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

May 07
We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

May 03
Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Apr 26

Incyte: A Potential GARP Superstar

Feb 27

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Feb 02
Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Oct 31
Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Knight's affiliate files for Brazilian approval of cancer drug tafasitamab

Oct 07

Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart

Sep 29

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Sep 15

Incyte wins approval of Pemazyre for rare blood cancer

Aug 26

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

Aug 02

With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Jul 27
With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Incyte Corp. Should Move Higher (Technical Analysis)

Jul 18

Incyte: Growth Drivers Are Coming

Jun 17

Earnings and Revenue Growth Forecasts

NasdaqGS:INCY - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265,1311,2751,5371,57718
12/31/20254,6359721,2501,14422
12/31/20244,2027919333122
9/30/20244,0763217102N/A
6/30/20243,85797-140-61N/A
3/31/20243,768745791821N/A
12/31/20233,696598449496N/A
9/30/20233,609425566632N/A
6/30/20233,513366698781N/A
3/31/20233,470324561649N/A
12/31/20223,395341892970N/A
9/30/20223,331876711802N/A
6/30/20223,320945665760N/A
3/31/20223,115933609759N/A
12/31/20212,986949568749N/A
9/30/20212,913535543741N/A
6/30/20212,721338450668N/A
3/31/20212,703478569765N/A
12/31/20202,667-296-312-125N/A
9/30/20202,457-335-266-100N/A
6/30/20202,388-191-108-12N/A
3/31/20202,229-376-227-128N/A
12/31/20192,159447633711N/A
9/30/20192,108405589663N/A
6/30/20192,006306476592N/A
3/31/20191,997253392471N/A
12/31/20181,882109263336N/A
9/30/20181,798-10990163N/A
6/30/20181,729-102N/A17N/A
3/31/20181,534-167N/A101N/A
12/31/20171,536-313N/A-93N/A
9/30/20171,419-155N/A91N/A
6/30/20171,306-154N/A133N/A
3/31/20171,226-107N/A34N/A
12/31/20161,106104N/A305N/A
9/30/20161,023151N/A280N/A
6/30/201694174N/A193N/A
3/31/201685849N/A189N/A
12/31/20157547N/A89N/A
9/30/2015634-86N/A61N/A
6/30/201564413N/A81N/A
3/31/2015581-33N/A53N/A
12/31/2014511-48N/A26N/A
9/30/2014485-54N/A-30N/A
6/30/2014372-136N/A-70N/A
3/31/2014374-101N/A-47N/A
12/31/2013355-83N/A9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INCY's forecast earnings growth (46.3% per year) is above the savings rate (2.6%).

Earnings vs Market: INCY's earnings (46.3% per year) are forecast to grow faster than the US market (15.3% per year).

High Growth Earnings: INCY's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: INCY's revenue (8.9% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: INCY's revenue (8.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: INCY's Return on Equity is forecast to be high in 3 years time (24.7%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y